Microba Life Sciences Limited

As of June 30, 2025, Microba Life Sciences Limited carries a market capitalization of 43.78M, placing it among publicly traded companies globally. Its enterprise value stands at 35.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Microba Life Sciences Limited's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2025, Microba Life Sciences Limited has 515.03M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 2.43, and the price-to-book ratio stands at 1.35.

These figures are as of June 30, 2025. The EV/Sales ratio of 2.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 35.27M versus a market cap of 43.78M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Microba Life Sciences Limited maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.94, indicating elevated leverage, while an interest coverage ratio of -194.18 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2025, Microba Life Sciences Limited posted a negative return on equity (ROE) of -40.54, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -28.33, reflecting losses generated across the asset base. Inventory turnover of 3.94 indicates how many times Microba Life Sciences Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, Microba Life Sciences Limited recorded an income tax benefit of -106,594.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -15.05M and -14.94M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Microba Life Sciences Limited's stock has declined approximately 52.56% over the past 52 weeks. The 50-day moving average sits at 0.05, while the 200-day moving average is 0.06.

Over the twelve months ended June 30, 2025, Microba Life Sciences Limited generated 15.67M in revenue and converted that into -14.94M in net income, yielding earnings per share of -0.03. EBITDA reached -20.18M, while operating income came in at -24.61M.

As of June 30, 2025, Microba Life Sciences Limited holds 11.74M in cash and equivalents against 3.23M in total debt, resulting in a net debt position of -10.53M. Total book value stands at 32.49M, with working capital of 8.83M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Microba Life Sciences Limited posted a gross margin of 47.49, reflecting its pricing power and cost economics. The operating margin of -157.05 and net profit margin of -95.34 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -12.76, meaning Microba Life Sciences Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Microba Life Sciences Limited's most recent stock split took place on October 23, 2023 with a 151:160 split ratio.

As of June 30, 2025, Microba Life Sciences Limited has an Altman Z-Score of -5.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.